Prediction of angiographic stabilization/regression of coronary atherosclerosis by a risk factor graph

European Journal of Preventive Cardiology

Volumn 7, Issue 6, 2000, Pages 415-423

  Feeman, William E ^a   Niebauer, Josef ^b  

^a Herzzentrum Leipzig GmbH ^*  (United States)

^b UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

Author keywords

angiogram; coronary atherosclerosis; regression; stabilization; therapy of dyslipidemia

Indexed keywords

LIPID;

ANGIOCARDIOGRAPHY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DYSLIPIDEMIA; HUMAN; LIPID BLOOD LEVEL; META ANALYSIS; PRIORITY JOURNAL; RISK FACTOR;

CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE;

EID: 84992792154     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/204748730000700604     Document Type: Article

References (21)

1. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. JAMA 1984; 251: 351–364.
2. Frick H, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et el. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237–1245.
3. Scandinavian Simvastatin Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival. Lancet 1994; 344: 1383–1389.
4. Shepherd J, Cobbe S, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307.
5. The Long Term Intervention with Pravastatin in Ischemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary artery disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357.
6. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, et al Effects on coronary artery disease of lipid lowering diet, or diet plus cholestyramine in the St. Thomas Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563–569.
7. Brensike JF, Levy RJ, Kelsey SF, Passamani ER, Richardson JM, Loh IK, et al Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984; 69: 313–324.
8. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, et al Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemia (POSCH). N Engl J Med 1990; 323: 946–955.
9. Frick M, Syvanne M, Nieminen MS, Kauma H, Majaholme S, Virtanen V, et al Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 1997; 96: 2137–2143.
10. Schuler G, Hambrecht R, Schlierf G, Niebauer J, Hauer K, Neumann J, et al Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation 1992; 86: 1–11.
11. Brown G, Albers JJ, Fisher L, Schaefer SM, Lin JT, Kaplan C, et al Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289–1298.
12. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ, Hones PH, West S, et al Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80: 278–286.
13. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME, et al Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLACI): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995; 26: 1133–1139.
14. Azen SP, Mack WJ, Hemphill-Cashin L, LaBree L, Shircore AM, Selzer RH, et al Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 1996; 96: 34–41.
15. Feeman WE. Jr The Bowling Green Study of the primary and secondary prevention of atherosclerosis: descriptive analysis, findings, applications and conclusions. Ohio J Sci 1992; 12: 153–181.
16. Feeman WE. Jr The Bowling Green Study of the primary and secondary prevention of atherosclerosis: update 1991–1993. Ohio J Sci 1994; 9: 105–112.
17. Feeman WE. Jr The role of cigarette smoking in atherothrombotic disease: an epidemiologic analysis. J Cardiovasc Risk 1999; 6: 333–336.
18. La Rosa J. Effect of statin drug treatment in risk of coronary disease with to attention to age and gender: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340–2346.
19. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Choleseterol in Adults. The Expert Panel. Arch Intern Med 1988; 148: 36–39.
20. Grundy SM, Billheimer D, Chalt A, Clark LT, Denke M, Havel RJ, et al Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) JAMA 1993; 269: 3015–3023.
21. Farb A, Burke AP, Tang AL, et al Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93: 1354–1363.